Literature DB >> 8592518

Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.

J Parma1, J Van Sande, S Swillens, M Tonacchera, J Dumont, G Vassart.   

Abstract

A series of somatic mutations of the TSH receptor gene have been demonstrated in hyperfunctioning thyroid adenomas. The mutations studied up to now cause constitutive (i.e. TSH-independent) activation of the cAMP-regulatory cascade only. As a follow-up to our original study, we have now completely sequenced exon number 10 of the TSH receptor gene in the same series of toxic adenomas. An activating mutation was found in nine of 11 tumors. In addition to the mutations already described, two isoleucine residues belonging to the first and second extracellular loops of the receptor (Ile486 and Ile568) were found mutated. Two different adenomas were found to harbor a different amino acid substitution at residue 486 (Ile486Phe, Ile486Met). Ile568 was mutated to threonine in one. When studied by transfection in COS-7 cells, all three mutations caused very strong activation of the cAMP-regulatory cascade. In addition, the Ile486Phe and, to a lesser extent, the Ile486Met and Ile568Thr mutants stimulated constitutively the inositol phosphate-diacylglycerol cascade. Our results demonstrate that 1) the first and second extracellular loops contribute to the silencing of the unliganded TSH receptor; 2) the two regulatory cascades normally under TSH control can be constitutively activated by somatic mutations of the receptor; 3) the TSH receptor can be activated by mutation of a large number of residues distributed over the first and second extracellular loops, the third intracellular loop, and the third, sixth, and seventh transmembrane segments; 4) activating mutations of the TSH receptor constitute the major cause of toxic adenomas, accounting for about 80% of the cases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592518     DOI: 10.1210/mend.9.6.8592518

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  33 in total

1.  Constitutively active mutants of 5-HT4 receptors are they in unique active states?

Authors:  S Claeysen; M Sebben; C Bécamel; M L Parmentier; A Dumuis; J Bockaert
Journal:  EMBO Rep       Date:  2001-01       Impact factor: 8.807

Review 2.  Thyrotropin receptor mutations in thyroid diseases.

Authors:  P M Yen
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

3.  Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutation with weakly increased constitutive activity.

Authors:  Eijun Nishihara; Chun-Rong Chen; Takuya Higashiyama; Yumiko Mizutori-Sasai; Mitsuru Ito; Sumihisa Kubota; Nobuyuki Amino; Akira Miyauchi; Basil Rapoport
Journal:  Thyroid       Date:  2010-10-07       Impact factor: 6.568

Review 4.  The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia.

Authors:  L M Calvi; E Schipani
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

5.  Activation of cyclic AMP-dependent kinase is required but may not be sufficient to mimic cyclic AMP-dependent DNA synthesis and thyroglobulin expression in dog thyroid cells.

Authors:  S Dremier; V Pohl; C Poteet-Smith; P P Roger; J Corbin; S O Doskeland; J E Dumont; C Maenhaut
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

6.  Ras homolog enriched in striatum inhibits the functional activity of wild type thyrotropin, follicle-stimulating hormone, luteinizing hormone receptors and activating thyrotropin receptor mutations by altering their expression in COS-7 cells.

Authors:  P Agretti; G De Marco; A Pinchera; P Vitti; J Bernal; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

Review 7.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

Review 8.  Molecular insights into TSH receptor abnormality and thyroid disease.

Authors:  D Russo; F Arturi; E Chiefari; S Filetti
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

9.  Alanine-261 in intracellular loop III of the human gonadotropin-releasing hormone receptor is crucial for G-protein coupling and receptor internalization.

Authors:  D B Myburgh; R P Millar; J P Hapgood
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

10.  Evidence for cooperative signal triggering at the extracellular loops of the TSH receptor.

Authors:  Gunnar Kleinau; Holger Jaeschke; Sandra Mueller; Bruce M Raaka; Susanne Neumann; Ralf Paschke; Gerd Krause
Journal:  FASEB J       Date:  2008-04-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.